Navigation Links
Blood Pressure Lowering Effect of Hypertension Treatment Device Further Validated in New Studies
Date:6/16/2008

ted that patients were compliant with the device and that

no adverse side effects were reported.

-- PS33/THU/01 -- Pooled results from two separate studies led by Profs.

Rosenthal and the Erdine study (above), utilizing 24-hour ambulatory

blood pressure monitoring demonstrated that RESPeRATE benefits

uncontrolled-hypertension sufferers. The analysis demonstrated a

clinically significant blood pressure reduction throughout both daytime

and nighttime. RESPeRATE was also found to independently reduce high

values of a risk-associated arterial property (S-D slope/AASI) derived

from the relationship between systolic and diastolic pressures.

-- PS34/MON/08 -- Data analysis led by Dr. Benjamin Gavish, chief

scientific officer, InterCure, Ltd., of a study performed in Italy,

conducted by Prof. Gianfranco Parati, explored, for the first time, the

linear relationships between systolic and diastolic blood pressure from

beat-to-beat measurements. The derived risk-related parameters (S-D

slope and AASI) are acutely influenced by breathing patterns and neck

suction.

-- PS34/MON/18 -- An Israeli study, conducted by Dr. Iddo Ben-Dov and

Prof. Michael Burzstyn from Hadassah Medical Center, and Dr. Benjamin

Gavish, concluded that the ratio of systolic to diastolic blood

pressure variability is shown to be a blood pressure-independent

predictor of mortality, associated with the linear relationship between

systolic and diastolic pressures.

-- PS18/WED/58 -- An Italian, randomized controlled study, led by Prof. G.

Parati from the University of Milan-Bicocca concluded that device-

guided paced breathing at home is feasible and improves prognostically

relevant clinical and instrumental parameters in heart failure

patients. It is recommended as an additiona
'/>"/>

SOURCE InterCure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
2. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
3. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
4. Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
5. Study Shows Lantus(R) Helped People Living with Type 2 Diabetes Reach the ADAs Recommended Target for Blood Sugar Control
6. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
7. Observational Studies Assess the Potential Impact of Limiting Erythropoiesis-Stimulating Agent Availability on Frequency of Blood Transfusions
8. New Study Linking High Normal Blood Pressure to Significant Cardiovascular Risk
9. Naturally Occurring Compounds in Cocoa Tied to Blood Flow Improvements for Adults With Type 2 Diabetes
10. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014  Sutro Biopharma today announced that ... one of 2014,s Fierce 15 biotechnology companies, designating it ... in the industry.  "Sutro has earned ... as well as industry partners for what promises to ... bispecifics," says John Carroll , editor of ...
(Date:9/22/2014)... YORK , Sept. 22, 2014 ... exclusive, global license agreement with Plasma Technologies LLC ... proprietary plasma fractionation process. Concurrently, the Company announced ... to strategically refocus and rebrand the company as ... a national listing for its common shares. ...
(Date:9/22/2014)... Research and Markets  has announced the addition of ... report to their offering. The ... professional and in-depth study on the current state of ... Chinese situation. The report provides a basic ... industry chain structure. The diclofenac market analysis is provided ...
Breaking Medicine Technology:FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6Global and Chinese Diclofenac Industry Report 2014 2
... 24, 2011 Thomas Huxtable and his wife, Danielle, filed ... Inc. seeking compensation for injuries caused by the failure of ... has been recalled.  John David Hart of the Law Offices ... attorney representing Mr. and Mrs. Huxtable in the lawsuit filed ...
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), ... human disease, announced today that Pablo Lapuerta, M.D. has ... for directing clinical development of Lexicon,s drug candidates from ... Lapuerta has 15 years of pharmaceutical industry experience in ...
Cached Medicine Technology:DePuy Recalled Hip Device Lawsuit Filed in Austin, Texas 2Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer 2Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer 3
(Date:9/22/2014)... 22, 2014 Quincy Bioscience, one ... States, promotes National Self-Improvement Month this ... individuals should have access to self-improvement resources, especially ... The demand for products that preserve health is ... before. For over six years, Quincy Bioscience has ...
(Date:9/22/2014)... Scans of young children,s brains might help predict ... potentially allow doctors to identify those with dyslexia ... suggests. "Early identification and interventions are extremely ... most neurodevelopmental disorders," the study,s senior author, Dr. ... adolescent psychiatry at University of California, San Francisco ...
(Date:9/22/2014)... In a continued effort to support the ... launching an awareness campaign inspired by the ice bucket ... to raise awareness and funds for the cause. , ... the air and trying to catch it while blindfolded. ... nominee does not complete the challenge within 24 hours ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 The struggles ... English proficiency (LEP) patients has been well-documented—reportedly, language barriers ... repeat visits to the emergency room and an increased ... , At Sanford Health, the largest medical facility ... a rising LEP population necessitated the need for ...
(Date:9/22/2014)... Tenn. (PRWEB) September 22, 2014 ... contact center and customer service solutions. , WHAT: ... is focused on customer care for the connected ... landscapes continue to offer new challenges and opportunities ... to helping attendees identify best practices, network and ...
Breaking Medicine News(10 mins):Health News:Quincy Bioscience Promotes National Self-Improvement Month 2Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 2Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 3Health News:Healthcare Cost Savings Case Study:Stratus Video Interpreting Assists Sanford Health System in Accommodating Increasing LEP Population,Saves a Predicted $100,000 Per Year 4Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2
... is associated with an increased risk of heart failure and ... concludes a study published on bmj.com today. ... continued use of rosiglitazone for most patients. Rosiglitazone and ... are widely used for the treatment of type 2 diabetes. ...
... year, 500,000 project to co-ordinate European and international ... treat malaria. The CRIMALDDI project (Coordination, Rationalisation ... Initiatives) is being led by the Liverpool School ... players in the antimalarial drug discovery fields including ...
... Having 45 million doses by Oct. 15 will still be ... Health experts do not believe that the delay in receiving ... protect Americans against the newly circulating virus. , But having ... than the originally anticipated 120 million doses, does throw a ...
... , MONROVIA, Calif., Aug. 20 STAAR Surgical Company ... minimally invasive ophthalmic products, today reported on the status of its application ... , , As anticipated, the Ministry of Health, Labour ... in Japan, at which time the STAAR Visian ICL products were considered ...
... ... and innovative charitable program that provides free hair restoration services to children suffering from ... ... , the world,s first online social network community dedicated to all-things hair loss has ...
... ... Sparsense, the developer of a novel image and signal processing ... firm. The exclusive partnership will allow the development of various custom ... applications. The new technology can be applied to MRI, MR video ...
Cached Medicine News:Health News:Diabetes drug linked to increased risk of heart failure 2Health News:LSTM to lead EU project to coordinate antimalarial drug research 2Health News:Swine Flu Vaccine Delay Manageable, Experts Say 2Health News:Swine Flu Vaccine Delay Manageable, Experts Say 3Health News:STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens (ICL(TM)) 2Health News:STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens (ICL(TM)) 3Health News:STAAR Surgical Reports Progress on Japanese Application for Approval of Visian(TM) Implantable Collamer(R) Lens (ICL(TM)) 4Health News:Hair Loss Website Launches Program for Children 2Health News:Mantaro Partners with Sparsense to Deliver High Performance Digital Image and Signal Processing Solutions 2Health News:Mantaro Partners with Sparsense to Deliver High Performance Digital Image and Signal Processing Solutions 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: